APRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Aprea Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.53−0.05 (-8.88%)
Close on Oct 19, 2026
- Market cap
- $28.47M
- P/E (TTM)
- –
- Dividend yield
- –
Aprea Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Aprea Therapeutics | Industry median |
|---|---|---|
| Market Cap | $6.70M | $166.30M |
| Enterprise Value | -$34.53M | $88.19M |
| PB Ratio | 0.17 | 2.03 |
| P/TBV Ratio | 0.17 | 2.29 |
Income (trailing twelve months)
| Measure | Aprea Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$13.22M | -$21.40M |
| Net Income | -$12.31M | -$22.46M |
| EBITDA | -$13.20M | -$16.91M |
| EPS (Diluted) | -$1.08 | -$0.83 |
Returns
| Measure | Aprea Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -47.4% | -53.2% |
| Return on Assets (ROA) | -41.3% | -40.9% |
| Return on Capital Employed (ROCE) | -33.7% | -38.1% |
Balance sheet
| Measure | Aprea Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $41.23M | $61.43M |
| Net Cash (Debt) | $41.23M | $15.35M |
| Net Cash Per Share | $3.27 | $0.66 |
| Equity (Book Value) | $38.47M | $49.09M |
| Book Value Per Share | $3.06 | $1.37 |
| Tangible Book Value | $38.47M | $23.52M |
| Working Capital | $38.82M | $76.81M |
Financial position
| Measure | Aprea Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 13.55 | 3.34 |
| Quick Ratio | 13.33 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Aprea Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$12.17M | -$12.35M |
Efficiency
| Measure | Aprea Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$1.54M | -$703.34K |
| Employee Count | 8 | 74 |
Dividends and yields
| Measure | Aprea Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -183.6% | -23.3% |
| Buyback Yield | -599.6% | -0.59% |
| Shareholder Yield | -599.6% | 0.00% |
Shares
| Measure | Aprea Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 12,591,100 | 58,127,000 |
| Shares Change (YoY) | 243.0% | 10.9% |
| Shares Change (QoQ) | 3.41% | 0.54% |
| Float | 11,786,400 | 49,136,700 |
| Shares Held by Insiders | 6.39% | 11.6% |
| Shares Held by Institutions | 20.5% | 59.4% |
Taxes
| Measure | Aprea Therapeutics | Industry median |
|---|---|---|
| Income Tax | $0 | $79.87K |
Scores
| Measure | Aprea Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -10.15 | -0.22 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from Aprea Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.